📰 Thomas Biegi News
Page 6 - Thomas Biegi News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Thomas Biegi. Real-time updates on events, politics, business and more.
November 28, 2022
PLANEGG / MUNICH, GERMANY / ACCESSWIRE / November 28, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) publishes its financial calendar dates for the year 2023:Publication of Interim Statement / ReportConference
November 28, 2022
28.11.2022 - PLANEGG / MUNICH, GERMANY / ACCESSWIRE / November 28, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) publishes its financial calendar dates for the year 2023:Publication of Interim Statement / ReportConference CallYear-End Results 2022March 15, 2023 // ...
November 16, 2022
Monjuvi U.S. net product sales of US$ 22.2 million (€ 21.9 million) for the third quarter of 2022 Presentation of preliminary results from phase 1/2 study of tulmimetostat (CPI-0209) supporting its
November 16, 2022
EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim StatementMorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results 16.11.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, November 16, 2022 MorphoSys AG...
November 14, 2022
EQS-News: MorphoSys AG / Key word(s): Study results MorphoSys Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for...
October 27, 2022
EQS-News: MorphoSys AG / Key word(s): MiscellaneousGSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis   27.10.2022 / 08:50 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich,...
October 27, 2022
PLANEGG / MUNICH, GERMANY / ACCESSWIRE / October 27, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner, GSK plc (GSK), provided an update on the ContRAst phase III program
October 27, 2022
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors 27.10.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Re...
October 27, 2022
The findings, including encouraging preliminary efficacy data in various tumor types, were presented during the 34th EORTC-NCI-AACR SymposiumPLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 27, 2022 / MorphoSys
October 21, 2022
MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022Preliminary Q3 2022 Monjuvi U.S. net product sales of US$ 22.2 million (€ 21.9 million)Anticipated full year